Compounded tirzepatide from 503a pharmacies: what's actually legal now?

What did @kristinastout actually say?

On February 19, 2025, this nurse practitioner claimed she successfully ordered compounded tirzepatide from a 503A pharmacy with "no issues," that all the 503A pharmacies she had spoken to were still making it, and closed with a pitch to visit her clinic if patients couldn't get it elsewhere. That last part is worth noting, because it frames a regulatory gray area as a simple supply problem with a commercial solution.

The core claim is narrow but consequential: that 503A compounding pharmacies remained open for business on tirzepatide as of mid-February 2025. That's a time-sensitive claim about a fast-moving regulatory situation, which makes it genuinely useful or genuinely dangerous depending on how accurate it is.

Does the science and regulation back this up?

Partially, but the framing is incomplete in ways that matter. The FDA declared tirzepatide (brand name Zepbound and Mounjaro) to be no longer in shortage in October 2024. Under federal law, 503A compounding pharmacies are generally permitted to compound copies of commercially available drugs only when those drugs are on the FDA shortage list. Once a drug comes off that list, the legal basis for compounding it gets much shakier.

The FDA set a wind-down period, with an original deadline of late February 2025 for 503A pharmacies to stop compounding tirzepatide for non-patient-specific reasons. That deadline was later extended to March 2025 following legal challenges from compounding pharmacy trade groups, including the Outsourcing Facilities Association. So yes, on February 19, 2025, some 503A pharmacies were technically still operating. But "still making it" and "legally permitted to keep making it" are two different things, and the video treats them as the same.

What did they get wrong, and what did they get right?

Credit where it's due: she is correct that, on the specific date she recorded this, some 503A compounding pharmacies were still filling tirzepatide orders. That's factually defensible. She's also a licensed nurse practitioner, which gives her more standing to discuss this than most TikTok voices.

What she got wrong, or at least glossed over, is the legal trajectory. The FDA's position was unambiguous: 503A compounders should be winding down tirzepatide production, not business as usual. The fact that pharmacies were still filling orders does not mean those orders were within the intended regulatory window. She presents this as a stable supply situation when it was actually a countdown clock.

She also never mentions that compounded tirzepatide is not the same as FDA-approved tirzepatide. Compounded drugs skip the FDA's approval process for safety, efficacy, and manufacturing standards. That's not a small footnote. A patient hearing "tirzepatide is still available" may not understand they're being offered a different product with a different regulatory profile.

What should you actually know?

The tirzepatide compounding situation changed rapidly through early 2025. After the FDA removed tirzepatide from the shortage list in October 2024, 503A pharmacies entered a grace period to wind down production. Legal challenges from compounding industry groups pushed some of those deadlines into March and April 2025, which is why some pharmacies were still operating in February when this video was recorded. But "still available" at that moment was not the same as "available indefinitely."

The FDA has been consistent that compounded tirzepatide is not FDA-approved and that patients should be aware of the distinction. The agency's 2024 shortage determination was based on manufacturer supply data, though some patient advocates and compounding groups disputed whether access had truly normalized for all patients.

If you were considering compounded tirzepatide based on videos like this one, it's worth asking your prescriber about the current regulatory status, not a February 2025 TikTok snapshot.